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A survey was carried out among EBMT centers about the use of busulfan for 51 
conditioning in allogeneic stem cell transplantation. Of 109 responding centers, 106 52 
used busulfan for conditioning, 102 in conventional myeloablative doses, and 93 in 53 
reduced doses (RIC). The route of administration was mostly intravenous, but 54 
approximately ten per cent of the centers gave the drug orally. The number of doses in 55 
i.v. administration varied and was in myeloablative conditioning mostly one (50 centers) 56 
or four (43 centers) doses a day. Seventeen of the 106 centers used pharmacokinetics 57 
for dose adjustment in myeloablative conditioning, 9 in RIC. The details of 58 
pharmacokinetic monitoring varied markedly. Three quarters of the centers reported 59 
adjusting the dose based on obesity in myeloablative conditioning and about 60 % in 60 
RIC. The most common method for dose calculation was ideal body weight + 0.25 x 61 
(actual body weight – ideal body weight). In conclusion, the present survey showed 62 
marked heterogeneity in the current practices of busulfan administration for 63 
conditioning. The impact of the heterogeneity is not well known. Due to this and the 64 
scarcity of support from controlled clinical studies, no clear guidelines can be presented, 65 









Busulfan-based conditioning in various combinations is widely used in allogeneic 73 
hematopoietic stem cell transplantation (HSCT). Busulfan was initially given orally in 74 
myeloablative doses, and for practical reasons typically in four daily doses on four 75 
consecutive days (1). Erratic absorption from the gut and thereby variable 76 
bioavailability resulted in deviations from the target exposure to the drug, causing 77 
sometimes undue organ toxicity. Therefore many centers began to adjust the doses 78 
based on pharmacokinetic (PK) measurements. With the introduction of an 79 
intravenous formulation, options for the administration increased. Intravenous 80 
administration was easier in practice, allowed more precise dosing and has widely 81 
replaced oral administration, although a minority of centers continue to use the oral 82 
route. The role of PK measurements, therapeutic drug monitoring (TDM), remains 83 
unclear particularly in i.v. administration (2). The practice of busulfan administration 84 
for conditioning at transplant centers is evidently heterogeneous, and details in which 85 
the policies of centers are likely to differ include the route of administration, number 86 
of daily doses, use of PK measurements, and adjustment of doses in obese patients. 87 
The possible impact of such differences on the outcome is unknown. The Transplant 88 
Complications Working Party of the European Society for Blood and Marrow 89 
Transplantation (EBMT) has carried out a survey among EBMT centers about their 90 
practice in the use of busulfan for conditioning in allogeneic HSCT in adults, with the 91 
aim of using the obtained information as support for potential recommendations 92 





All allogeneic transplant centers reporting to the EBMT and treating adult patients were 96 
invited to participate in the survey. The questionnaire included 47 questions about the 97 
indications for busulfan conditioning, doses used, routes of administration, days of 98 
administration, number of daily doses, use of pharmacokinetics, adjustment of doses 99 
based on obesity, and preparations used ( Supplementary material, Table 1). The survey 100 
was carried out from February to May 2017. Two reminders were sent to centers that 101 
had not responded. The survey was strictly anonymous, the information of the 102 
reporting center and person was only known to the data center but not to the 103 
investigators. Associations between center characteristics and busulfan use policy were 104 
tested with Fisher´s exact test. The studied parameters were transplant program size 105 
(50 or more vs. fewer allogeneic transplantations according to EBMT 2015 annual 106 
survey) (3), center experience (25 years or more vs. less), JACIE accreditation status, 107 
and gross national income per capita (GNI) of the country (www.Worldbank.com). 108 
The intensity of conditioning, myeloablative (MAC) or reduced intensity (RIC), was 109 
registered as reported by the center. In some instances more than one alternative 110 
applied, and some questions in the questionnaire were not answered, leading to 111 
uneven sums.  112 







One hundred and nine centers, 28% of all EBMT centers performing allogeneic 118 
transplantations to adult patients, participated and sent their report. Of these centers 119 
106 used busulfan for conditioning, 102 in conventional myeloablative doses, and 93 in 120 
reduced doses. The distribution by country of the participating centers using busulfan 121 
conditioning is shown in Table 1. The diseases for which the transplantations were 122 
carried out are shown in Table 2. 123 
The route of busulfan administration was mostly intravenous, but approximately ten 124 
per cent of the centers gave the drug orally (Fig. 1A). The characteristics of the centers 125 
using oral or i.v. administration did not differ in transplant program size, center 126 
experience, JACIE accreditation status, or GNI of the country. 127 
Ninety-three centers determined the busulfan dose based on weight, seven centers 128 
based on body surface area.  129 
Myeloablative oral doses, 16 mg/kg, were always given on four days, on each day four 130 
doses of 1 mg/kg, subject to dose modification in case TDM was used. In i.v. 131 
administration, the myeloablative total dose was most commonly approximately 12.8 132 
mg/kg (69 centers). Other doses called myeloablative were given at 27 centers. When 133 
the dose was calculated based on body surface area, the total dose was 520 mg/m2.  134 
Myeloablative i.v. doses were always administered in four days. The number of daily 135 
doses was mostly one (50 centers) or four (43 centers) (Fig. 1B).  136 
In RIC transplantations, the most common policy was to reduce the number of days 137 
from that used in i.v. MAC, whereas the daily dose and the administration schedule 138 
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commonly remained the same. Sixty-five per cent of the centers reported giving 139 
busulfan on two days in RIC. The number of daily i.v. busulfan doses in RIC 140 
transplantations was most commonly one (40 centers) or four (28 centers) (Fig. 1B). 141 
Overall, 17 of the 106 centers used PK measurements for busulfan dose adjustment in 142 
MAC, including 9 using such measurements also in RIC. The intensity of the conditioning 143 
did not significantly affect the proportion of centers using TDM (Fig. 1C). There was no 144 
significant difference between centers giving oral or intravenous busulfan in the use of 145 
pharmacokinetics for dose adjustment (Fig. 1D). The use of PK measurements was not 146 
significantly associated with transplant program size, center experience, JACIE 147 
accreditation status, or GNI of the country. 148 
The PK measurements were carried out after the first dose in 12 centers while four 149 
centers allowed variability in timing; no data was received from one center. One center 150 
used a test dose 1-2 weeks prior to conditioning. The sampling for TDM depended on 151 
the number of daily doses and included at least 3 samples to cover the concentration-152 
time curve, but the timing of sampling varied greatly, all centers having their own 153 
schedule. Busulfan concentration was measured with liquid chromatography coupled 154 
with mass spectrometry in 8 centers, and with liquid chromatography  based on other 155 
detection methods in 5 centers. This information was lacking from 4 centers.The 156 
parameter used for dose adjustment was based on the area under the curve (AUC).  The 157 
specific AUC-based parameters varied between centers, and no two target AUCs were 158 
reported identically. However, the estimate of the reported target ranges, translated to 159 
the total AUC after a single dose, was from less than 900 to 1500 µmol/l x min, 160 
corresponding to a cumulative AUC of the four-day treatment of about 60 to 100 mg/l 161 
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x h, i.e. the reported target values were similar to previous reports and 162 
recommendations (2). The model for AUC calculation was one-compartment model 163 
(n=4), noncompartmental analysis (n=3) or Bayesian modeling (n=2); this information 164 
was lacking from 8 centers. Four centers reported receiving the results of PK 165 
measurements on the day of the sampling, 10 centers on the next day, and one center 166 
on the third day. 167 
Eight centers reported alternatives in the procedure of busulfan administration or 168 
target AUC depending on the disease, other components of the conditioning, or study 169 
protocols.  170 
Approximately three quarters of the centers reported to adjust the busulfan dose based 171 
on obesity in MAC and about 60 % in RIC (Table 3). The definition of obesity and the 172 
way the dose was adjusted varied. The most common method for dose calculation was 173 
to use AIBW-25, ideal body weight + 0.25 x (actual body weight – ideal body weight) (4).   174 
 175 
Discussion 176 
The present survey showed a marked heterogeneity among allogeneic transplant 177 
centers in the details of their current use of busulfan for pre-transplant conditioning in 178 
allogeneic transplantations in adults. This is likely to be due to the limited evidence 179 
available to support any given practices and limitations in facilities for TDM. 180 
The Practice Guidelines Committee of the American Society for Blood and Marrow 181 
Transplantation (ASBMT) recently published a report on their effort to develop an 182 
evidence-based review about personalizing busulfan-based conditioning (2). They 183 
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found that the published literature was too heterogeneous and lacked adequately 184 
powered and sufficiently controlled studies for their aim to be feasible. However, they 185 
presented a document addressing topics of practical relevance in busulfan conditioning. 186 
In line with the observations of the Practice  Guidelines Committee, the findings of the 187 
present survey about the heterogeneity of the current practices reflect the lack of 188 
standard procedures in busulfan-based conditioning.  189 
 As expected, busulfan was used in conventional or reduced doses in a large majority of 190 
centers and for a wide spectrum of disorders. With the 28 % response rate there may 191 
be some reporting bias, but the presented findings are likely to reflect in a satisfactory 192 
way the general state of the use of busulfan conditioning at EBMT centers.  193 
Busulfan was administered intravenously in close to 90 per cent of the centers. The 194 
obvious advantages of the i.v. route are easy administration, avoiding problems caused 195 
by gastrointestinal irritation, more precise dosing avoiding the variable absorption 196 
from the gut and thereby variable bioavailability, and avoiding first-pass metabolism in 197 
the liver. A reason for using the oral route is lower cost. There were no significant 198 
differences in the characteristics of the centers giving the drug orally and those using 199 
the i.v. route. 200 
Oral busulfan is administered in four daily doses for practical reasons, difficulties with 201 
swallowing large numbers of tablets and gastrointestinal irritation. When i.v. busulfan 202 
became available, the traditional schedule was initially transferred to i.v. 203 
administration. However, evidence has since been presented that the daily dose can 204 
be given in one dose without untoward consequences (5,6). The pharmacokinetics are 205 
similar with one and four daily doses, but as obvious, the peak concentration of 206 
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busulfan is higher and the trough concentration lower with single daily doses (6). 207 
Generally no significant differences in adverse effects related to this difference in peak 208 
concentrations have been observed, and there is to our knowledge no evidence to 209 
suggest a difference in clinical efficacy. There is an obvious practical advantage in giving 210 
one daily infusion instead of four. Despite this, close to half of the centers reported 211 
dividing the daily i.v. busulfan dose in four doses.  212 
The policy with busulfan dose adjustment based on PK measurements should be based 213 
on documentation of clinical benefits, reducing complications or improving efficacy. 214 
Several reports have shown an association between high exposure to busulfan and 215 
increased toxicity (7-14), and low busulfan exposure has been shown to correlate with 216 
more frequent graft rejection (9, 14-16). Several studies have indicated an association 217 
between busulfan exposure and transplant-related mortality, or event-free or overall 218 
survival (14, 17-20). As to specific diseases, busulfan exposures have been shown to 219 
associate with relapse rate in previously untreated CML, higher exposures leading to 220 
lower relapse rate (21). In a randomized prospective trial in AML and MDS, 221 
pharmacokinetically guided busulfan delivery led to lower relapse risk and treatment-222 
related mortality as well as to higher overall and event-free survival compared to fixed 223 
dose administration (22). However, the documentation from controlled clinical trials of 224 
concrete clinical benefits of busulfan TDM is still limited, and there is no general 225 
consensus about the utility of pharmacokinetics for busulfan dose adjustment (2). It is 226 
also to be noted that the impact of busulfan TDM may be different in different 227 
conditioning regimens. Overall, there are no widely followed guidelines about the use 228 
of PK measurements in this context. The report from the ASBMT Practice Guidelines 229 
Committee (2) concludes that busulfan TDM is currently considered unnecessary in RIC 230 
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transplantations. There was no conclusive statement of a recommendation to monitor 231 
busulfan concentrations in transplantations with conventional busulfan doses. Another 232 
report from the same organization states that all regimens with a more than 12 mg/kg 233 
oral dose equivalent are recommended to have PK targeting as appropriate for the 234 
disease (23). 235 
One of the centers participating in the present survey used a test dose before the 236 
conditioning to calculate the busulfan doses based on pharmacokinetics. This approach 237 
has recently been applied by several groups (11, 22, 24-28), but the ASBMT document 238 
did not recommend the use of a test dose (2). 239 
The present survey shows that busulfan TDM is used in only a minority, approximately 240 
15 % of the EBMT centers. Among patients reported to the CIBMTR (Center for 241 
International Bone and Marrow Transplant Research) in 2008, more than 60 % of those 242 
who received oral busulfan and 50 % of those receiving i.v. busulfan had PK data (29). 243 
Oral administration, with potentially erratic absorption from the gut, could be expected 244 
to be a particular reason to use TDM, but in the present study there was no significant 245 
difference in the use of busulfan measurements between centers using oral or i.v. 246 
administration. Similarly, conventional busulfan doses could have been expected to be 247 
a stronger indication to TDM compared to reduced doses, but busulfan PK 248 
measurements were used approximately equally often in connection with conventional 249 
and RIC doses. Reasons for this situation may include uncertainty about concrete clinical 250 
benefit, but possibly also limited availability of laboratory service for busulfan 251 
measurements, AUC calculations and dose recommendations may be contributing 252 
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factors in the present state. The center characteristics of those using or not using PK  253 
measurements did not differ significantly. 254 
There was marked variability in the practical details of the TDM, in the timing of 255 
measurements, units used, and the method to calculate AUC; no two centers reported 256 
an identical TDM protocol. However, the estimate of the reported target ranges, 257 
translated to the total AUC after a single dose, indicated that the target values were 258 
similar to previous reports and recommendations (2). These results seem to reflect the 259 
current situation that there are recommendations for the concentration target for 260 
busulfan, but consensus guidelines concerning the method used for AUC estimation are 261 
lacking. 262 
Approximately three quarters of the centers reported adjusting myeloablative busulfan 263 
doses based on obesity, whereas about 25 per cent did not make such adjustments. 264 
There was marked variation in how the adjustments were determined, but the most 265 
common policy was based on AIBW-25, in line with the ASBMT recommendations (23). 266 
In the survey by the EBMT Acute Leukemia Working Party of chemotherapy dose 267 
adjustment for obese patients in HSCT  (30), 80.5 per cent of the centers adjusted the 268 
doses. Sixty-two percent used body mass index as the parameter for defining obesity, 269 
and the most common methods for dose calculation were based on actual body weight 270 
or AIBW-25, each in approximately one third of the centers. There is to our knowledge 271 
no solid clinical evidence of the benefits of dose adjustment based on obesity, but as 272 
the drug exposure may become markedly different in grossly obese patients depending 273 
on whether adjustments are or are not made (30), a study focusing on this issue would 274 
be desirable. 275 
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Constitutional genetic polymorphisms might be a factor in individualizing busulfan 276 
doses. Particularly associations between the polymorphisms of genes associated with 277 
glutathione S-transferases and the clinical outcomes after busulfan conditioning have 278 
been a topic of discussion (2). However, the available documentation of the impact of 279 
such associations has been regarded as insufficient for a recommendation to use 280 
genetic polymorphism for personalizing busulfan doses in routine clinical practice (2). 281 
The present survey shows marked heterogeneity in the current practices of busulfan 282 
administration for conditioning. Due to this and the scarcity of support from controlled 283 
clinical studies, no clear guidelines based on solid documentation or dominating 284 
practice can be presented. However, some prevailing policies can be identified and 285 
commented on:  286 
- A large majority of centers give busulfan i.v., but a significant minority still use the 287 
oral route. Low costs favor oral administration, but otherwise there are  both 288 
practical and theoretical advantages for  i.v. administration.  289 
- I.v. busulfan can be given in one daily dose, but almost half of the centers divide the 290 
daily dose in four infusions. There is no evidence to suggest any advantage to the 291 
divided doses, and therefore a single daily dose seems to be the policy to be 292 
recommended. 293 
- PK-based dose adjustment is only used in a small minority of centers, even in 294 
transplantations with myeloablative busulfan doses. Although busulfan TDM seems 295 
logical, the evidence for clinical benefit especially in i.v. administration is limited. 296 
Several studies from recent years have presented data to support the use of 297 
pharmacokinetics for dose adjustment, but at this time it does not seem possible to 298 
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present well-founded recommendations for the use of busulfan TDM, particularly 299 
not in i.v. administration. 300 
- There has been a lack of consistency in AUC based dose adjustment practices, 301 
particularly regarding the AUC based target parameter used, demonstrating a need 302 
for development of best-practice guidelines. 303 
- The policy of dose adjustment for obesity is heterogeneous. Busulfan TDM would in 304 
principle be logical in obese patients, but documentation of its usefulness in this 305 
situation is obviously lacking. 306 
In conclusion, the clinical impact of the observed heterogeneity in the application of 307 
test strategies, the use of PK guided dose measurements, or adjustments for body 308 
weight remain poorly defined. The effects of such variability on outcomes such as 309 
toxicity and relapse would ideally be evaluated in randomized trials. 310 
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Legend to Figure 439 
 440 
Figure 1. Administration of busulfan in myeloablative (MAC) and reduced intensity 441 
(RIC) conditioning; numbers of centers. A: route of administration; B: number of 442 
daily doses; C: therapeutic drug monitoring (TDM) used; D: TDM used in relation 443 
to route of administration. 444 
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